ERBB2 and breast cancer: These data are consistent with an US SEER analysis suggesting that adjuvant chemotherapy benefit in older patients were restricted to those with ER-negative disease.28,30 In HER2-positive EBC patients, fewer breast cancer deaths occurred in those who received chemotherapy with or without trastuzumab although the differences were not statistically significant in a matched analysis.